Načítá se...
Novel Experimental Drugs for Treatment of Multiple Myeloma
Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging from two to more than 10 years. By using new drugs such as proteasome inh...
Uloženo v:
| Vydáno v: | J Exp Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7955760/ https://ncbi.nlm.nih.gov/pubmed/33727866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S265288 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|